Business Context and Reporting Period
Company: Dogwood Therapeutics, Inc. (DWTX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Dogwood is a pre-revenue, development-stage biopharmaceutical company focused on treating pain and neuropathy. The company operates primarily through two key programs: Halneuron (a non-opioid Nav 1.7 modulator for chemotherapy-induced neuropathic pain) and SP16 (a peptide for neuropathy and nerve damage). In October 2024, the company completed a business combination with Pharmagesic (Holdings) Inc., acquiring the Halneuron program. The company is classified as a "smaller reporting company."
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(34,257,370) | $(12,349,724) |
| Operating Expenses | $27,968,445 | $12,227,248 |
| Research & Development (R&D) | $21,866,071 | $3,530,913 |
| General & Administrative (G&A) | $6,102,374 | $8,696,335 |
| Cash and Cash Equivalents (Year-End) | $6,524,744 | $14,847,949 |
| Net Cash Used in Operating Activities | $(15,618,651) | $(8,790,805) |
| Accumulated Deficit | $(108,076,316) | $(73,818,946) |
| Debt Outstanding | $0 | $15,381,077 (Related Party) |
Note: The 2025 R&D expense includes approximately $12.0 million in non-cash acquired In-Process Research and Development (IPR&D) related to the SP16 license agreement.
Material Changes vs. Prior Period
- Significant Increase in Net Loss: Net loss increased by approximately $21.9 million (177%) year-over-year, driven primarily by a $6.1 million loss on debt conversion and a $12.0 million non-cash charge for acquired IPR&D.
- R&D Expense Surge: R&D expenses increased by $18.3 million, largely due to the capitalization and immediate expensing of the SP16 license and increased clinical trial costs for the Halneuron Phase 2b study (HAL-CINP-203).
- Debt Extinguishment: A $19.5 million related-party loan was converted into Series A-1 Preferred Stock in March 2025, resulting in a $6.1 million loss on debt conversion. No debt remained outstanding at year-end.
- Equity Transactions: The company completed a registered direct offering in March 2025 raising approximately $4.25 million net. All outstanding Series A, A-1, and A-2 Preferred Stock converted to Common Stock in November 2025.
- Cash Position: Cash and cash equivalents decreased by approximately $8.3 million, reflecting high operating burn rates despite financing activities.
Guidance, Outlook, and Risks
Outlook and Guidance
Management anticipates that cash on hand ($6.5 million) plus net proceeds from a January 2026 offering ($11.4 million) will fund operations through the third quarter of 2026. The company expects to incur significant additional operating losses for the foreseeable future as it advances clinical trials. No specific financial guidance was provided beyond the runway estimate.
Management Commentary
- Halneuron Progress: The HAL-CINP-203 Phase 2b trial commenced in Q1 2025. An interim analysis in December 2025 indicated separation from placebo in a 97-patient subset. Top-line results are expected in Q3 2026.
- SP16 Program: The company acquired a global license for SP16 in September 2025. A Phase 1b study, funded by a National Cancer Institute grant, is projected to start in mid-2026.
- Manufacturing: The company is developing a synthetic formulation of Halneuron to replace natural harvesting, aiming for cost-effectiveness and extended IP protection.
Risks and Contingencies
- Going Concern: The independent auditor has issued an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern without additional capital. The company has an accumulated deficit of over $108 million.
- Capital Needs: The company will require additional financing beyond Q3 2026 to continue clinical trials and operations. Failure to secure funding could force delays or termination of programs.
- Clinical Risk: Success is heavily dependent on the Halneuron Phase 2b results. Failure to demonstrate efficacy or safety would materially harm the business.
- Regulatory Risk: No products are currently approved. Regulatory approval is uncertain and costly.
- Stock Listing: The company previously received notices regarding non-compliance with Nasdaq minimum bid price and stockholders' equity requirements but regained compliance in 2024 and 2025 respectively.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $11.4 million raised in January 2026 to fund operations through Q3 2026 and the timeline for the next capital raise.
- Halneuron Interim Data: Review the full details of the December 2025 interim analysis for the HAL-CINP-203 trial to assess the statistical significance and clinical relevance of the separation from placebo.
- SP16 Valuation: Assess the strategic value of the SP16 license given the $12.0 million immediate expense and the reliance on a grant-funded Phase 1b study.
- Debt Conversion Loss: Understand the impact of the $6.1 million non-cash loss on debt conversion on the company's reported net loss and equity structure.
- Going Concern Status: Monitor the company's ability to raise capital in the current market environment to avoid a liquidity crisis post-Q3 2026.